CureVac N.V. (NASDAQ:CVAC) Receives $6.83 Average PT from Analysts

Shares of CureVac N.V. (NASDAQ:CVAC) have been assigned an average rating of “Hold” from the six research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $6.8333.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CureVac in a report on Tuesday.

CureVac Stock Down 2.8%

CureVac stock opened at $4.16 on Wednesday. CureVac has a fifty-two week low of $2.47 and a fifty-two week high of $5.72. The firm has a market capitalization of $933.25 million, a price-to-earnings ratio of 5.78 and a beta of 1.77. The stock’s fifty day moving average is $5.20 and its two-hundred day moving average is $5.29. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.69 and a current ratio of 3.70.

CureVac (NASDAQ:CVAC) last released its quarterly earnings results on Monday, November 24th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.07. The business had revenue of $63.53 million during the quarter, compared to the consensus estimate of $21.40 million. CureVac had a negative return on equity of 23.03% and a net margin of 199.92%. Analysts predict that CureVac will post 0.72 EPS for the current fiscal year.

Hedge Funds Weigh In On CureVac

Several hedge funds have recently bought and sold shares of CVAC. Caitong International Asset Management Co. Ltd lifted its position in shares of CureVac by 354.8% in the second quarter. Caitong International Asset Management Co. Ltd now owns 5,608 shares of the company’s stock valued at $30,000 after acquiring an additional 4,375 shares in the last quarter. Headlands Technologies LLC acquired a new position in CureVac in the 2nd quarter valued at about $35,000. Kathmere Capital Management LLC purchased a new position in CureVac in the 2nd quarter valued at about $60,000. L2 Asset Management LLC acquired a new stake in shares of CureVac during the 2nd quarter worth about $70,000. Finally, Integrated Wealth Concepts LLC boosted its stake in shares of CureVac by 25.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock worth $42,000 after purchasing an additional 3,000 shares during the last quarter. Hedge funds and other institutional investors own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.